Aptose Cash And Short Term Investments vs Other Stockholder Equity Analysis

APTO Stock

USD 0.98 0.18 15.52%

Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Cash And Short Term Investments and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Cash And Short Term Investments vs Other Stockholder Equity

Cash And Short Term Investments vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Cash And Short Term Investments account and Other Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.

The correlation between Aptose Biosciences' Cash And Short Term Investments and Other Stockholder Equity is 0.34. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Cash And Short Term Investments and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Aptose Biosciences are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Cash And Short Term Investments i.e., Aptose Biosciences' Cash And Short Term Investments and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.34

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Aptose Biosciences balance sheet. This account contains Aptose Biosciences investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Aptose Biosciences fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Other Stockholder Equity

Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 31st of May 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 5.8 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	94K	788K	1.4M	1.5M
Interest Income	94K	788K	1.4M	1.5M

Net Interest Income Interest Income

Aptose Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Common Stock Total Equity	Short Term Debt	Common Stock
Total Assets		0.09	0.25	0.99	0.74	-0.97	-0.39	0.34	0.96	0.55	0.64	1.0	0.51	0.56	0.11	-0.3	0.37	0.28	0.08	1.0	-0.02	-0.19	0.93	0.47	0.02	0.72
Other Current Liab	0.09		0.95	-0.04	0.44	-0.06	-0.85	0.69	0.1	0.67	-0.12	0.06	0.86	-0.01	0.08	0.87	0.88	0.94	0.91	0.08	0.86	-0.22	0.37	0.81	-0.04	0.53
Total Current Liabilities	0.25	0.95		0.12	0.63	-0.22	-0.93	0.87	0.25	0.78	-0.03	0.23	0.94	0.09	0.23	0.72	0.96	1.0	0.81	0.24	0.91	-0.27	0.47	0.88	-0.04	0.69
Total Stockholder Equity	0.99	-0.04	0.12		0.67	-0.96	-0.27	0.23	0.96	0.46	0.66	0.99	0.4	0.56	0.08	-0.4	0.25	0.15	-0.02	0.99	-0.14	-0.16	0.89	0.37	0.02	0.64
Property Plant And Equipment Net	0.74	0.44	0.63	0.67		-0.71	-0.63	0.74	0.72	0.85	0.49	0.73	0.73	0.33	0.32	0.08	0.64	0.65	0.43	0.74	0.46	-0.09	0.75	0.7	-0.04	0.81
Net Debt	-0.97	-0.06	-0.22	-0.96	-0.71		0.34	-0.32	-1.0	-0.54	-0.73	-0.97	-0.46	-0.34	-0.16	0.28	-0.3	-0.24	-0.11	-0.97	0.07	0.2	-0.91	-0.45	-0.06	-0.66
Retained Earnings	-0.39	-0.85	-0.93	-0.27	-0.63	0.34		-0.83	-0.37	-0.72	-0.11	-0.36	-0.95	-0.21	-0.25	-0.55	-0.93	-0.93	-0.66	-0.38	-0.81	0.55	-0.57	-0.94	-0.13	-0.84
Accounts Payable	0.34	0.69	0.87	0.23	0.74	-0.32	-0.83		0.34	0.78	0.08	0.32	0.84	0.12	0.41	0.39	0.86	0.88	0.51	0.33	0.86	-0.25	0.44	0.77	-0.1	0.72
Cash	0.96	0.1	0.25	0.96	0.72	-1.0	-0.37	0.34		0.57	0.73	0.96	0.49	0.33	0.17	-0.24	0.33	0.28	0.15	0.96	-0.04	-0.21	0.92	0.47	0.07	0.66
Non Current Assets Total	0.55	0.67	0.78	0.46	0.85	-0.54	-0.72	0.78	0.57		0.34	0.53	0.8	0.16	0.24	0.38	0.75	0.8	0.66	0.55	0.62	-0.14	0.66	0.79	0.04	0.65
Other Assets	0.64	-0.12	-0.03	0.66	0.49	-0.73	-0.11	0.08	0.73	0.34		0.65	0.17	0.03	0.49	-0.31	0.03	0.0	0.08	0.64	-0.31	-0.15	0.59	0.25	0.2	0.37
Cash And Short Term Investments	1.0	0.06	0.23	0.99	0.73	-0.97	-0.36	0.32	0.96	0.53	0.65		0.49	0.56	0.1	-0.32	0.34	0.25	0.06	1.0	-0.05	-0.18	0.92	0.45	0.02	0.7
Common Stock Shares Outstanding	0.51	0.86	0.94	0.4	0.73	-0.46	-0.95	0.84	0.49	0.8	0.17	0.49		0.27	0.16	0.52	0.97	0.94	0.7	0.51	0.79	-0.31	0.67	0.93	-0.04	0.84
Short Term Investments	0.56	-0.01	0.09	0.56	0.33	-0.34	-0.21	0.12	0.33	0.16	0.03	0.56	0.27		-0.12	-0.33	0.25	0.1	-0.17	0.56	0.01	-0.05	0.49	0.2	-0.15	0.43
Non Current Liabilities Total	0.11	0.08	0.23	0.08	0.32	-0.16	-0.25	0.41	0.17	0.24	0.49	0.1	0.16	-0.12		-0.04	0.16	0.24	0.12	0.11	0.12	-0.3	0.14	0.24	0.22	0.24
Other Current Assets	-0.3	0.87	0.72	-0.4	0.08	0.28	-0.55	0.39	-0.24	0.38	-0.31	-0.32	0.52	-0.33	-0.04		0.56	0.7	0.89	-0.31	0.71	-0.13	0.01	0.49	-0.13	0.12
Other Stockholder Equity	0.37	0.88	0.96	0.25	0.64	-0.3	-0.93	0.86	0.33	0.75	0.03	0.34	0.97	0.25	0.16	0.56		0.96	0.69	0.36	0.84	-0.22	0.54	0.88	-0.03	0.77
Total Liab	0.28	0.94	1.0	0.15	0.65	-0.24	-0.93	0.88	0.28	0.8	0.0	0.25	0.94	0.1	0.24	0.7	0.96		0.81	0.27	0.91	-0.27	0.49	0.88	-0.05	0.7
Property Plant And Equipment Gross	0.08	0.91	0.81	-0.02	0.43	-0.11	-0.66	0.51	0.15	0.66	0.08	0.06	0.7	-0.17	0.12	0.89	0.69	0.81		0.08	0.65	-0.11	0.38	0.67	-0.07	0.37
Total Current Assets	1.0	0.08	0.24	0.99	0.74	-0.97	-0.38	0.33	0.96	0.55	0.64	1.0	0.51	0.56	0.11	-0.31	0.36	0.27	0.08		-0.03	-0.19	0.93	0.47	0.01	0.72
Non Currrent Assets Other	-0.02	0.86	0.91	-0.14	0.46	0.07	-0.81	0.86	-0.04	0.62	-0.31	-0.05	0.79	0.01	0.12	0.71	0.84	0.91	0.65	-0.03		-0.21	0.16	0.72	-0.15	0.51
Intangible Assets	-0.19	-0.22	-0.27	-0.16	-0.09	0.2	0.55	-0.25	-0.21	-0.14	-0.15	-0.18	-0.31	-0.05	-0.3	-0.13	-0.22	-0.27	-0.11	-0.19	-0.21		-0.29	-0.47	-0.48	-0.45
Net Tangible Assets	0.93	0.37	0.47	0.89	0.75	-0.91	-0.57	0.44	0.92	0.66	0.59	0.92	0.67	0.49	0.14	0.01	0.54	0.49	0.38	0.93	0.16	-0.29		0.66	0.03	0.77
Common Stock Total Equity	0.47	0.81	0.88	0.37	0.7	-0.45	-0.94	0.77	0.47	0.79	0.25	0.45	0.93	0.2	0.24	0.49	0.88	0.88	0.67	0.47	0.72	-0.47	0.66		0.24	0.82
Short Term Debt	0.02	-0.04	-0.04	0.02	-0.04	-0.06	-0.13	-0.1	0.07	0.04	0.2	0.02	-0.04	-0.15	0.22	-0.13	-0.03	-0.05	-0.07	0.01	-0.15	-0.48	0.03	0.24		0.12
Common Stock	0.72	0.53	0.69	0.64	0.81	-0.66	-0.84	0.72	0.66	0.65	0.37	0.7	0.84	0.43	0.24	0.12	0.77	0.7	0.37	0.72	0.51	-0.45	0.77	0.82	0.12

Click cells to compare fundamentals

Aptose Biosciences Account Relationship Matchups

Aptose Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	126.3M	82.5M	51.0M	12.9M	12.3M
Other Current Liab	3.1M	4.1M	6.0M	5.7M	13.9M	14.6M
Total Current Liabilities	5.5M	6.8M	8.2M	12.3M	15.2M	16.0M
Total Stockholder Equity	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.7M)
Property Plant And Equipment Net	1.7M	1.2M	788K	1.5M	1.1M	574.3K
Net Debt	(78.3M)	(116.3M)	(38.5M)	(35.7M)	(8.2M)	(8.6M)
Retained Earnings	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(512.9M)	(487.3M)
Accounts Payable	2.0M	2.2M	1.7M	6.3M	3.5M	3.7M
Cash	79.8M	117.4M	39.1M	37.0M	9.2M	15.8M
Non Current Assets Total	1.7M	1.2M	788K	1.5M	1.1M	1.7M
Cash And Short Term Investments	97.6M	122.4M	79.1M	47.0M	9.2M	8.7M
Common Stock Shares Outstanding	3.3M	5.5M	5.9M	6.2M	6.8M	7.1M
Short Term Investments	798K	440K	17.8M	5M	40.0M	10.0M
Liabilities And Stockholders Equity	100.5M	126.3M	82.5M	51.0M	12.9M	12.3M
Non Current Liabilities Total	1.0M	535K	115K	1.0M	617.8K	586.9K
Other Current Assets	141K	129K	133K	257K	2.6M	2.8M
Other Stockholder Equity	34.6M	50.9M	63.7M	68.9M	71.8M	75.4M
Total Liab	6.6M	7.3M	8.3M	13.3M	15.8M	16.6M
Property Plant And Equipment Gross	1.7M	1.2M	323K	211K	3.9M	4.1M
Total Current Assets	98.8M	125.1M	81.7M	49.5M	11.8M	11.2M
Non Currrent Assets Other	(94.0)	(48.0)	465K	1.3M	1.2M	1.2M
Intangible Assets	1.0	142.0	94.0	48.0	43.2	41.04
Net Tangible Assets	93.8M	118.9M	74.2M	37.7M	43.4M	45.6M
Common Stock Total Equity	365.5M	429.5M	437.4M	437.5M	503.1M	528.3M
Retained Earnings Total Equity	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(417.9M)	(397.0M)
Common Stock	365.5M	429.5M	437.4M	437.5M	442.5M	231.4M
Property Plant Equipment	1.6M	1.1M	788K	211K	189.9K	364.1K
Capital Surpluse	34.6M	50.9M	63.7M	68.9M	79.2M	51.4M
Net Invested Capital	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Net Working Capital	93.2M	118.3M	73.6M	37.2M	(3.4M)	(3.2M)
Capital Stock	365.5M	429.5M	437.4M	437.5M	444.8M	435.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:

How To Invest In Aptose

Details

Is Aptose Stock a good investment?

Details

What is Aptose Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Aptose Stock analysis

When running Aptose Biosciences' price analysis, check to measure Aptose Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aptose Biosciences is operating at the current time. Most of Aptose Biosciences' value examination focuses on studying past and present price action to predict the probability of Aptose Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aptose Biosciences' price. Additionally, you may evaluate how the addition of Aptose Biosciences to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is Aptose Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.28)

Return On Assets

(1.02)

Return On Equity

(2.94)

The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptose Cash And Short Term Investments vs Other Stockholder Equity Analysis

Cash And Short Term Investments vs Other Stockholder Equity

Cash And Short Term Investments vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Other Stockholder Equity

Aptose Biosciences fundamental ratios Correlations

Aptose Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptose Biosciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Aptose Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Net Debt	- 0.96	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.95	Retained Earnings